Welcome to our dedicated page for Avita Medical SEC filings (Ticker: AVHHL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Avita Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Avita Medical's regulatory disclosures and financial reporting.
AVITA Medical, Inc. filed a shelf registration statement to offer up to $200,000,000 of common stock, preferred stock, warrants and units under a Form S-3 shelf prospectus dated March 31, 2026. The prospectus states that specific terms for each offering will be set forth in a prospectus supplement. The company's common stock trades on Nasdaq under the symbol RCEL; the prospectus notes a Nasdaq closing price of $3.63 per share as of March 30, 2026. The prospectus says proceeds are expected to be used for general corporate purposes, including capital expenditures and working capital, with precise uses to be specified in future prospectus supplements.
AVITA Medical, Inc. CFO David D. O'Toole increased his stake by buying 1,800 shares of common stock in an open-market purchase at $4.78 per share. After this transaction, he directly owns 141,927 shares, which the disclosure notes include unvested restricted stock units (RSUs).
AVITA Medical, Inc. director Woody Joseph Fralin filed an initial statement of beneficial ownership on Form 3. The filing identifies him as a director of the company and reports no buy, sell, acquire, or dispose transactions in AVITA Medical, Inc. securities.
AVITA Medical, Inc. Chief Financial Officer David D. O'Toole reported an open-market purchase of 3,000 shares of common stock on February 19, 2026 at $4.15 per share. Following this buy, his directly held stake increased to 140,127 shares, which includes unvested restricted stock units.
AVITA Medical, Inc. CFO David D. O'Toole reported equity compensation awards consisting of stock options and restricted stock units. He acquired 155,510 stock options with an exercise right to buy common shares, and 105,470 shares of common stock in the form of restricted stock units, both at a stated price of $0.00 per share.
The RSUs represent rights to receive one share of common stock each, vesting in three equal annual installments starting 12 months after the February 18, 2026 grant date. The stock options also vest in three equal annual installments beginning on the first anniversary of the same grant date, aligning his compensation with longer-term company performance.
AVITA Medical, Inc. reported that Chief Legal Officer Nicole Kelsey received equity awards consisting of stock options and restricted stock units. She was granted stock options for 145,060 shares at an exercise price of $0.0000 per share and 98,390 shares of Common Stock through restricted stock units.
The restricted stock units each represent the right to receive one share of Common Stock and vest in three equal annual installments beginning 12 months after the February 18, 2026 grant date. The stock options vest in three equal annual installments beginning on the first anniversary of the February 18, 2026 grant date, aligning the awards with multi-year service and performance.
AVITA Medical, Inc. reports in its annual filing that it remains a high-growth, loss-making acute wound care company built around its RECELL autologous cell harvesting platform and new products Cohealyx and PermeaDerm.
The company posted a net loss of $48.6 million in 2025 and has an accumulated deficit of $408.4 million, while targeting long-term profitability through broader use of RECELL in burns, traumatic and surgical wounds and international expansion. AVITA added a new senior secured credit facility of up to $60 million, drawing $50 million and using part of the proceeds to refinance prior debt. It emphasizes extensive FDA approvals, growing clinical and health-economic evidence, and a sizable patent and trademark portfolio as competitive strengths, but warns that execution, reimbursement, regulatory, manufacturing, cybersecurity, and high leverage risks could materially affect results.
AVITA Medical reported fourth quarter 2025 revenue of $17.6 million, down slightly from $18.4 million a year earlier, as reimbursement headwinds continued to weigh on sales. Gross margin was 81.2%, below the prior year, but operating expenses fell to $24.7 million, helping keep the quarterly net loss flat at $11.6 million.
For full-year 2025, revenue grew about 11% to $71.6 million, while the net loss narrowed to $48.6 million from $61.8 million as the company cut sales, marketing, and administrative costs. AVITA ended 2025 with $18.2 million in cash and marketable securities and subsequently closed a five-year credit facility of up to $60 million, using initial proceeds to refinance debt. For 2026, it expects revenue of $80–$85 million, roughly 12–19% growth, supported by improved Medicare payment rates and advancing clinical studies.
The Vanguard Group filed an amended Schedule 13G reporting its beneficial ownership of Avita Medical Inc common stock. Vanguard reports beneficially owning 1,444,579 shares, representing 4.73% of the outstanding common stock, with shared voting power over 190,616 shares and shared dispositive power over all 1,444,579 shares.
Vanguard indicates it holds the securities in the ordinary course of business and not to change or influence control of Avita Medical. The filing notes an internal realignment on January 12, 2026, after which certain Vanguard subsidiaries or business divisions are expected to report beneficial ownership separately.
AVITA Medical, Inc. entered into a new five-year senior secured credit facility of up to $60 million with Perceptive Credit Holdings V, LP. The company drew an initial $50 million on closing and used it to fully repay and terminate its prior credit agreement with an affiliate of OrbiMed Advisors.
The loan bears interest at the SOFR rate (with a minimum of 4.00%) plus 7.50%, and includes prepayment premiums of 1% to 10%, an exit fee in certain circumstances, and customary events of default and covenants. AVITA must maintain minimum trailing twelve-month net revenue levels and at least $5 million of unrestricted cash.
As part of the financing, AVITA agreed to issue a 10-year warrant to purchase up to 500,000 shares of common stock, with an additional 150,000 shares becoming issuable if the additional loan commitment is drawn. The warrant’s exercise price is based on the 10-day volume-weighted average price and is subject to shareholder approval and Australian Securities Exchange requirements. AVITA also furnished a press release updating expected fourth quarter and full-year 2025 revenue and providing 2026 revenue guidance.